Search academic texts

Information × Registration Number 0221U106443, 0118U003732 , R & D reports Title Develop new methods of combined treatment for patients with breast cancer with an unfavorable prognosis. popup.stage_title Head Smolanka Ivan , Доктор медичних наук Registration Date 07-12-2021 Organization National Cancer Institute popup.description2  The subject of the study was 480 patients with breast cancer. The aim of the work is to increase the effectiveness of treatment and improve the quality of life of patients with breast cancer with an unfavorable prognosis by developing new methods of combination therapy. The direct results of treatment of patients with breast cancer with an unfavorable prognosis using standard and developed methods of neoadjuvant polychemotherapy with magnetic therapy are analyzed. Comparative analysis of intermediate results shows a significant advantage of methods of selective intra-arterial polychemotherapy with magnetic therapy over standard systemic chemotherapy. The results of treatment of patients with edematous forms of breast cancer were evaluated according to the developed method, where a selective intra-arterial route of administration of chemotherapeutic drugs in combination with magnetothermy was used. Complete regression was observed in 5 patients (7.0 ± 1.4%) in the main group, and in 2 (2.8 ± 2.3%) patients of the control group. Partial regression was observed in 34 patients (47.8 ± 2.6%) in the main group and in 21 (29.5 ± 4.1%) patients of the control group. Stabilization was observed in 29 patients (40.8 ± 3.7%) in the main group and in 41 (57.7 ± 5.2%) patients in the control group. Progression of the disease was observed in 2 patients (2.8 ± 2.3%) in the first group and in 7 (9.8 ± 3.2%) patients of the control group. The developed technique allowed to perform radical surgery in 82% of patients in the main group due to the high rate of partial regression of the tumor. Regression of metastatically affected lymph nodes was determined in 56 (78.8% ± 3.2%) patients of the main group and in 41 (57.7 ± 5.2%) patients of the control group. Calculations of the overall survival rate for a period of 24 months have been performed. The best result was observed in the main group: 55 patients (77.4 ± 4.2%), against 48 patients (67.6 ± 3.7%) in the control group. Product Description popup.authors Ivankova Oksana M. Dosenko Iryna V. Kostryba Oleksii I. Loboda Andriy D. Lyashenko Andrij O. popup.nrat_date 2021-12-07 Close